ADAPT-M: a workflow for rapid, quantitative in vitro measurements of enriched protein libraries.

Publication date: Jul 15, 2026

Protein-protein interactions underpin most cellular processes, and engineered binders present powerful tools for probing biology and developing novel therapeutics. However, scalable, quantitative characterization of large numbers of candidates remains a major bottleneck. Here we show that ADAPT-M (Affinity Determination by Adaptation of ProTein binders for Microfluidics) enables rapid, parallel measurement of binding affinities and dissociation behavior directly from enriched display libraries in under one week, without requiring gene synthesis or hands-on protein purification. Applied to a computationally designed library targeting the SARS-CoV-2 Omicron BA. 1 receptor binding domain, ADAPT-M recovered most highly enriched variants and revealed that many display-enriched binders lacked measurable binding in vitro, highlighting limitations of screening alone. ADAPT-M enabled quantitative characterization of dozens of binders in parallel and selection of lead candidates for structural analysis. Unexpectedly, structural and mutational studies revealed that designed binding interfaces were preserved despite engaging alternative epitopes. By bridging screening and scalable in vitro validation, ADAPT-M accelerates protein binder discovery and supports data-driven protein engineering.

Open Access PDF

Concepts Keywords
Adapt
Binders
Binding
Candidates
Characterization
Designed
Display
Enriched
Libraries
Parallel
Protein
Quantitative
Rapid
Scalable

Semantics

Type Source Name
disease MESH dissociation
pathway REACTOME Reproduction
disease MESH included
disease MESH Aga2
disease MESH glass
pathway REACTOME Translation
disease MESH CDR3
disease MESH severe acute respiratory syndrome
disease MESH COVID 19
drug DRUGBANK Amino acids
disease MESH face
drug DRUGBANK Serine
drug DRUGBANK L-Alanine
drug DRUGBANK Water
drug DRUGBANK Glycerin
disease MESH PBS
drug DRUGBANK Myricetin
drug DRUGBANK Fluorescein
drug DRUGBANK Streptomycin
drug DRUGBANK Trimebutine
pathway REACTOME Digestion
drug DRUGBANK Carbenicillin
drug DRUGBANK Kanamycin
drug DRUGBANK Propidium
drug DRUGBANK Iodide
drug DRUGBANK Hydrogen peroxide
drug DRUGBANK Nitrogen
drug DRUGBANK Toluene
disease MESH GPS
drug DRUGBANK Trehalose
disease MESH PDC
drug DRUGBANK Medical air
disease MESH Plan
disease MESH image
disease MESH hrs
drug DRUGBANK Potassium Chloride
drug DRUGBANK Coenzyme M
drug DRUGBANK Pentaerythritol tetranitrate
drug DRUGBANK Imidazole
drug DRUGBANK Sodium lauryl sulfate
disease MESH SDS
disease MESH Rad
drug DRUGBANK Isopropyl beta-D-thiogalactopyranoside
drug DRUGBANK Phosphate ion
drug DRUGBANK Bicine
drug DRUGBANK Biotin
pathway KEGG Homologous recombination
disease MESH APC

Original Article

(Visited 6 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *

ADAPT-M: a workflow for rapid, quantitative in vitro measurements of enriched protein libraries.

Publication date: Jul 15, 2026

Protein-protein interactions underpin most cellular processes, and engineered binders present powerful tools for probing biology and developing novel therapeutics. However, scalable, quantitative characterization of large numbers of candidates remains a major bottleneck. Here we show that ADAPT-M (Affinity Determination by Adaptation of ProTein binders for Microfluidics) enables rapid, parallel measurement of binding affinities and dissociation behavior directly from enriched display libraries in under one week, without requiring gene synthesis or hands-on protein purification. Applied to a computationally designed library targeting the SARS-CoV-2 Omicron BA. 1 receptor binding domain, ADAPT-M recovered most highly enriched variants and revealed that many display-enriched binders lacked measurable binding in vitro, highlighting limitations of screening alone. ADAPT-M enabled quantitative characterization of dozens of binders in parallel and selection of lead candidates for structural analysis. Unexpectedly, structural and mutational studies revealed that designed binding interfaces were preserved despite engaging alternative epitopes. By bridging screening and scalable in vitro validation, ADAPT-M accelerates protein binder discovery and supports data-driven protein engineering.

Open Access PDF

Concepts Keywords
Adapt
Binders
Binding
Candidates
Characterization
Designed
Display
Enriched
Libraries
Parallel
Protein
Quantitative
Rapid
Scalable

Semantics

Type Source Name
disease MESH dissociation
pathway REACTOME Reproduction
disease MESH included
disease MESH Aga2
disease MESH glass
pathway REACTOME Translation
disease MESH CDR3
disease MESH severe acute respiratory syndrome
disease MESH COVID 19
drug DRUGBANK Amino acids
disease MESH face
drug DRUGBANK Serine
drug DRUGBANK L-Alanine
drug DRUGBANK Water
drug DRUGBANK Glycerin
disease MESH PBS
drug DRUGBANK Myricetin
drug DRUGBANK Fluorescein
drug DRUGBANK Streptomycin
drug DRUGBANK Trimebutine
pathway REACTOME Digestion
drug DRUGBANK Carbenicillin
drug DRUGBANK Kanamycin
drug DRUGBANK Propidium
drug DRUGBANK Iodide
drug DRUGBANK Hydrogen peroxide
drug DRUGBANK Nitrogen
drug DRUGBANK Toluene
disease MESH GPS
drug DRUGBANK Trehalose
disease MESH PDC
drug DRUGBANK Medical air
disease MESH Plan
disease MESH image
disease MESH hrs
drug DRUGBANK Potassium Chloride
drug DRUGBANK Coenzyme M
drug DRUGBANK Pentaerythritol tetranitrate
drug DRUGBANK Imidazole
drug DRUGBANK Sodium lauryl sulfate
disease MESH SDS
disease MESH Rad
drug DRUGBANK Isopropyl beta-D-thiogalactopyranoside
drug DRUGBANK Phosphate ion
drug DRUGBANK Bicine
drug DRUGBANK Biotin
pathway KEGG Homologous recombination
disease MESH APC

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *